March 12, 2025Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced it has been recognized by Clarivate as the top-ranked medical technology company in the Top 100 Global Innovators 2025, reinforcing its global reputation as a leading healthcare innovator. A consistent high-performer, Philips has been included in this major assessment of global innovators for 12 consecutive years. Roy Jakobs, CEO of Royal Philips said: "At Philips, we've been innovating for over 130 years to improve people's lives. Innovation is our fundamental strength, the reason why customers choose us as their strategic partner and a key value driver for

Arkansas moms get access to customized content and information on essential state resources for a healthier pregnancy Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, and Ingeborg Initiatives are teaming up to provide all expectant parents in Arkansas with access to Philips Avent Pregnancy+ app with customized state-offered information and tools to increase access to care, improve health literacy and adopt healthy habits. State residents who download the Pregnancy+ app will automatically receive access to this premium, customized content. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310474786/en/P

AWS's AI services and global infrastructure support the expansion of Philips' healthcare informatics portfolio and product development for secure, interoperable, and data-driven healthcare Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ:AMZN), today announced that Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, has selected AWS as its preferred cloud provider to advance its business transformation and deliver secure and innovative healthcare informatics solutions globally. Philips' cloud-first, AI-enabled approach is improving the company's ability to deliver better care for more people, providing faster product development and reduced infra

Exane BNP Paribas upgraded Philips from Neutral to Outperform

UBS upgraded Philips from Neutral to Buy

Jefferies upgraded Philips from Underperform to Hold

6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)

20-F - KONINKLIJKE PHILIPS NV (0000313216) (Filer)

6-K/A - KONINKLIJKE PHILIPS NV (0000313216) (Filer)

Mr David Pyott to retire from Philips' Supervisory Board after his third consecutive term.Mr Bob White proposed as new member of the Supervisory Board.Ms Indra Nooyi and Ms Chua Sock Koong proposed for reappointment as members of the Supervisory Board.Mr Marnix van Ginneken proposed for reappointment as member of Philips' Board of Management. February 19, 2025Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced proposed Supervisory Board appointments and reappointments, and a proposed Board of Management reappointment. Mr David Pyott (British/American, 1953) will retire from Philips' Supervisory Board at the end of the Annu

January 9, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the appointment of Jie Xue as Chief Business Leader Precision Diagnosis, and Özlem Fidanci as Chief of International Region, both effective January 1, 2025. Ms. Xue and Ms. Fidanci have joined Philips' Executive Committee and report directly to Roy Jakobs, CEO of Philips.Ms. Xue joins Philips from GE Healthcare to lead the Precision Diagnosis business that was temporarily led by Bert van Meurs, who will continue to lead Philips' Image Guided Therapy business. Ms. Xue and Mr. Van Meurs will be jointly responsible for the Diagnosis & Treatment segment. Ms. F

July 3, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA))), a global leader in health technology, today announced the appointment of Ms Ling Liu as the Chief Region Leader of Philips Greater China, effective immediately. Ms Liu is now a member of Philips' Executive Committee, reporting to Philips CEO Roy Jakobs. She succeeds Andy Ho, who has decided to retire after a long and successful career. Ms Liu and Mr Ho continue to work together to ensure a smooth handover. "Ling is a talented, trusted leader and I am delighted that she will join Philips' Executive Committee as the Chief Region Leader of Philips Greater China," said Roy Jakobs, CEO of Royal Philips. "Sh

February 19, 2025Full Year and Q4 Group performance highlights Sales of EUR 18.0 billion in 2024, comparable sales growth 1%; EUR 5.0 billion in Q4, comparable sales growth 1%, despite double-digit decline in ChinaComparable order intake increased 1% in 2024; up 2% in Q4, despite double-digit decline in ChinaIncome from operations was EUR 529 million in 2024; EUR 199 million in Q4Adjusted EBITA margin increased 90 basis points to 11.5% of sales in 2024; up 60 basis points to 13.5% in Q4Net cash flow from operating activities was EUR 1,569 million in 2024; EUR 1,459 million in Q4Free cash flow was EUR 906 million in 2024; EUR 1,285 million in Q4Finalized Philips Respironics recall-related me

November 12, 2024 Designed specifically for use in radiation oncology, new Spectral CT 7500 RT enables personalized radiation therapy planning to deliver better care for more cancer patients Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced a major advance in radiation oncology with 510(k) clearance from the US Food and Drug Administration (FDA) for its new detector-based spectral computed tomography (CT) radiotherapy solution. Philips Spectral CT 7500 RT marks the next step in personalized cancer care by integrating the unique tumor visualization and tissue characterization capabilities of spectral CT into cancer trea

October 28, 2024 Third-quarter highlights Group sales amounted to EUR 4.4 billion, with flat comparable sales growthIncome from operations was EUR 337 millionAdjusted EBITA margin increased by 160 basis points from 10.2% to 11.8% of salesOperating cashflow of EUR 192 million, with a free cashflow of EUR 22 millionComparable order intake decreased by 2%, due to decline in ChinaOutlook for full-year 2024 revised to reflect deteriorated demand in China: comparable sales growth within an updated range 0.5%-1.5%, Adjusted EBITA margin at around 11.5%, the upper end of current range; free cashflow at around EUR 0.9 billion, at lower end of current range Roy Jakobs, CEO of Royal Philips:

SC 13D/A - KONINKLIJKE PHILIPS NV (0000313216) (Subject)

SC 13D/A - KONINKLIJKE PHILIPS NV (0000313216) (Subject)

SC 13D - KONINKLIJKE PHILIPS NV (0000313216) (Subject)